Developer docs
API playgroundTry for free, no card

Search company profiles

Polyphron

Full company profile

uuid00kd94e

Namestring
Polyphron
Legal namestring
Polyphron
Websiteurl
polyphron.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Polyphron is a privately held biotechnology company building an autonomous tissue foundry platform that uses AI and automation to manufacture human tissue from induced pluripotent stem cells (iPSCs). The foundry combines atlas-informed priors mined from developmental single-cell atlases, high-throughput 3D tissue manufacturing, non-destructive AI phenotyping across millions of cells, and Bayesian optimization in a closed-loop system that iteratively designs perturbations, tests them experimentally, and converges on target tissue structures. The company has demonstrated the platform across two tissue programs — cortical and cardiac — achieving 60% and 49% relative hit-rate improvements, 89.4° and 81.9° median directionality, and >70% reductions in experimental cost per iteration, with cross-donor trajectory transfer reducing experimental footprint 12-fold for newly onboarded donors.

Short descriptiontext

Polyphron builds an autonomous tissue foundry that uses AI and automation to manufacture reproducible human tissue from iPSCs at scale, serving pharmaceutical AI drug-discovery teams, regenerative medicine developers, and biological simulator researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew City, United States
HQ citystring
New City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
autonomous tissue engineering, iPSC-derived tissue manufacturing, biological simulation platform, regenerative medicine therapeutics, AI-driven drug validation
Industry4 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-driven Tissue Manufacturing Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Tissue Grafts
TypeOne Time License
Description

Immune-compatible iPSC-derived tissue grafts that can restore tissue function through direct transplantation into patients. This is described as a business line designed to throw off blockbusters, serving as both revenue driver and in vivo calibration layer for the biological simulator.

polyphron.com
2AI Validation Substrate Services
TypeSubscription Recurring
Description

High-fidelity human tissue produced at scale serves as validation substrate for AI-driven drug design and prediction models. Pharmaceutical and biotech companies can access tissue constructs for experimental validation of computational predictions.

polyphron.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Polyphron operates an autonomous tissue foundry platform that uses AI, Bayesian optimization, and automated wet-lab systems to manufacture human tissue from induced pluripotent stem cells (iPSCs) at scale. It produces high-throughput 3D tissue constructs, continuously monitors them via non-destructive AI phenotyping, and sells these tissue units as immune-compatible therapeutic grafts and as validation substrate for AI-driven drug discovery, alongside a biological simulator trained on the causal interventional data the foundry generates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Achieved 89.4° median directionality in cardiac tissue (vs 81.9° in controls) with near-zero variability
+4 more records
Product overview1 text field

Polyphron operates as an integrated platform combining three core products: the Autonomous Tissue Foundry (core manufacturing platform that produces human tissue from iPSCs using AI-driven closed-loop experimentation), the Biological Simulator (AI system trained on causal foundry data to predict biological responses to interventions), and the Therapeutic Program (tissue transplantation into patients that validates ex vivo predictions against human ground truth). The company also generates a proprietary Causal Interventional Dataset as a byproduct of foundry operations. These products form a closed loop where the foundry generates training data for the simulator, the simulator guides foundry experiments, and therapeutic implantation provides the highest-fidelity validation for both.

Product and service4 records
1Autonomous Tissue Foundry
CategoryCore platform / Tissue manufacturing
Description

Core manufacturing platform that produces specifiable, reproducible, scalable human tissue units from iPSCs for pharmaceutical, biotech, and clinical partners; uses atlas-informed priors, active learning, and non-destructive AI phenotyping to optimize tissue development across diverse donors.

2Biological Simulator
CategorySoftware / Predictive AI
Description

AI software product trained on foundry data that predicts how human tissue will respond to drugs, biologics, gene therapies, and combination regimens; validated against human ground truth through Polyphron's therapeutic implantation program.

3Therapeutic Tissue Grafts (Therapeutic Program)
CategoryRegenerative medicine / Therapeutic product
Description

Immune-compatible iPSC-derived tissue grafts that restore tissue function through direct transplantation into patients; designed as curative tissue replacement therapies for degenerative diseases and also serves as the in vivo validation ground truth for Polyphron's simulator.

4Causal Interventional Dataset
CategoryData product
Description

Proprietary dataset of causal interventional measurements on human tissue across genetically diverse donors; consumed by pharma, biotech, and AI biology organizations building biological simulators and validating computational predictions.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Polyphron and Cellino collaborated to demonstrate end-to-end tissue manufacturing across genetically diverse patient-derived iPSC lines. Cellino manufactured four clonal iPSC lines from demographically diverse donors using its automated optical bioprocess, while Polyphron's tissue foundry engineered them into structured cortical tissue constructs. The collaboration demonstrated cross-donor optimization capability where Polyphron's platform achieved high-quality tissue across all four donor backgrounds without re-optimizing for each new donor, treating genetic diversity as a programmable variable.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides organ-on-chip platforms with human tissue models for preclinical testing; relevant peer in the high-fidelity tissue validation substrate category.

TypeDirect peer
Description

Produces human iPSC-derived cells and tissues at scale using proprietary transcription factor-based reprogramming; comparable in the iPSC-derived tissue manufacturing space.

3Organoid Therapeutics
TypeDirect peer
Description

Develops iPSC-derived organoid platforms for disease modeling and therapeutic applications, directly comparable to Polyphron's iPSC-derived cortical and cardiac tissue foundry approach.

TypeBroad incumbent
Description

Operates a large-scale AI-driven biology platform combining wet-lab automation with computational models to generate training data; concept-level comparator to Polyphron's tissue foundry + biological simulator thesis.

TypeDirect peer
Description

Combines iPSC-derived tissues with AI-driven analysis platforms for cardiac and muscle drug discovery; mirrors Polyphron's combination of tissue manufacturing and AI phenotyping.

6Cytovia Therapeutics
TypeEmerging player
Description

Develops iPSC-derived cell therapies including NK and T-cell platforms; adjacent peer in the iPSC-derived therapeutic space where Polyphron's tissue transplantation program operates.

7CN Bio
TypeDirect peer
Description

Develops organ-on-chip and microphysiological systems for drug discovery, directly comparable to Polyphron's use of 3D tissue constructs as biological test units for pharma partners.

TypeDirect peer
Description

Automates iPSC manufacturing via optical bioprocessing and has collaborated with Polyphron on cross-donor tissue manufacturing; directly comparable in the iPSC and tissue platform space.

TypeDirect peer
Description

Produces iPSC-derived neurons, cardiomyocytes and other cell types for disease modeling and drug discovery; comparable as an iPSC-derived tissue/cell supplier serving pharma and academic customers.

TypeDirect peer
Description

Develops human iPSC-derived cardiac and other tissues for drug discovery and safety testing; operates in the same cardiac tissue foundry category as Polyphron's cardiac program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polyphron

AI-driven Tissue Manufacturing Platformpolyphron.com

Polyphron builds an autonomous tissue foundry that uses AI and automation to manufacture reproducible human tissue from iPSCs at scale, serving pharmaceutical AI drug-discovery teams, regenerative medicine developers, and biological simulator researchers.

What Polyphron does

Polyphron is a privately held biotechnology company building an autonomous tissue foundry platform that uses AI and automation to manufacture human tissue from induced pluripotent stem cells (iPSCs). The foundry combines atlas-informed priors mined from developmental single-cell atlases, high-throughput 3D tissue manufacturing, non-destructive AI phenotyping across millions of cells, and Bayesian optimization in a closed-loop system that iteratively designs perturbations, tests them experimentally, and converges on target tissue structures. The company has demonstrated the platform across two tissue programs — cortical and cardiac — achieving 60% and 49% relative hit-rate improvements, 89.4° and 81.9° median directionality, and >70% reductions in experimental cost per iteration, with cross-donor trajectory transfer reducing experimental footprint 12-fold for newly onboarded donors.

Polyphron firmographics

Firmographics
Name
Polyphron
Legal name
Polyphron
Website
https://polyphron.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Polyphron builds an autonomous tissue foundry that uses AI and automation to manufacture reproducible human tissue from iPSCs at scale, serving pharmaceutical AI drug-discovery teams, regenerative medicine developers, and biological simulator researchers.
Ownership category
akta.pro rank

Polyphron industry classification

Industry
Product category
AI-driven Tissue Manufacturing Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Autonomous tissue engineering
  • IPSC-derived tissue manufacturing
  • Biological simulation platform
  • Regenerative medicine therapeutics
  • AI-driven drug validation

Where Polyphron is headquartered

Location

Headquarters

HQ city
New City
HQ country
United States
HQ region
North America

Markets served

Polyphron business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Therapeutic Tissue Grafts: Immune-compatible iPSC-derived tissue grafts that can restore tissue function through direct transplantation into patients. This is described as a business line designed to throw off blockbusters, serving as both revenue driver and in vivo calibration layer for the biological simulator.
  2. AI Validation Substrate Services: High-fidelity human tissue produced at scale serves as validation substrate for AI-driven drug design and prediction models. Pharmaceutical and biotech companies can access tissue constructs for experimental validation of computational predictions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Polyphron product offering

Product offering

Core offering

Polyphron operates an autonomous tissue foundry platform that uses AI, Bayesian optimization, and automated wet-lab systems to manufacture human tissue from induced pluripotent stem cells (iPSCs) at scale. It produces high-throughput 3D tissue constructs, continuously monitors them via non-destructive AI phenotyping, and sells these tissue units as immune-compatible therapeutic grafts and as validation substrate for AI-driven drug discovery, alongside a biological simulator trained on the causal interventional data the foundry generates.

Product overview

Polyphron operates as an integrated platform combining three core products: the Autonomous Tissue Foundry (core manufacturing platform that produces human tissue from iPSCs using AI-driven closed-loop experimentation), the Biological Simulator (AI system trained on causal foundry data to predict biological responses to interventions), and the Therapeutic Program (tissue transplantation into patients that validates ex vivo predictions against human ground truth). The company also generates a proprietary Causal Interventional Dataset as a byproduct of foundry operations. These products form a closed loop where the foundry generates training data for the simulator, the simulator guides foundry experiments, and therapeutic implantation provides the highest-fidelity validation for both.

Differentiator

Problem solved

Functional benefit

Products and services

  • Autonomous Tissue Foundry Core manufacturing platform that produces specifiable, reproducible, scalable human tissue units from iPSCs for pharmaceutical, biotech, and clinical partners; uses atlas-informed priors, active learning, and non-destructive AI phenotyping to optimize tissue development across diverse donors.
  • Biological Simulator AI software product trained on foundry data that predicts how human tissue will respond to drugs, biologics, gene therapies, and combination regimens; validated against human ground truth through Polyphron's therapeutic implantation program.
  • Therapeutic Tissue Grafts (Therapeutic Program) Immune-compatible iPSC-derived tissue grafts that restore tissue function through direct transplantation into patients; designed as curative tissue replacement therapies for degenerative diseases and also serves as the in vivo validation ground truth for Polyphron's simulator.
  • Causal Interventional Dataset Proprietary dataset of causal interventional measurements on human tissue across genetically diverse donors; consumed by pharma, biotech, and AI biology organizations building biological simulators and validating computational predictions.

Quantifiable outcome

  • Achieved 89.4° median directionality in cardiac tissue (vs 81.9° in controls) with near-zero variability
  • +4 more outcomes

Companies that use Polyphron

Customer profile

Segments3 records

Ideal customer profiles3 records

Polyphron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Polyphron partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CellinocoreStrategic or Co-development Partner · 7 April 2026Polyphron and Cellino collaborated to demonstrate end-to-end tissue manufacturing across genetically diverse patient-derived iPSC lines. Cellino manufactured four clonal iPSC lines from demographically diverse donors using its automated optical bioprocess, while Polyphron's tissue foundry engineered them into structured cortical tissue constructs. The collaboration demonstrated cross-donor optimization capability where Polyphron's platform achieved high-quality tissue across all four donor backgrounds without re-optimizing for each new donor, treating genetic diversity as a programmable variable.

Scale indicators13 records

Recent moves5 records

Expansion highlights6 records

Polyphron competitors and assessment

Company assessment

Direct peers

  • Emulate: Provides organ-on-chip platforms with human tissue models for preclinical testing; relevant peer in the high-fidelity tissue validation substrate category.
  • BIT Bio: Produces human iPSC-derived cells and tissues at scale using proprietary transcription factor-based reprogramming; comparable in the iPSC-derived tissue manufacturing space.
  • Organoid Therapeutics: Develops iPSC-derived organoid platforms for disease modeling and therapeutic applications, directly comparable to Polyphron's iPSC-derived cortical and cardiac tissue foundry approach.
  • Curi Bio: Combines iPSC-derived tissues with AI-driven analysis platforms for cardiac and muscle drug discovery; mirrors Polyphron's combination of tissue manufacturing and AI phenotyping.
  • CN Bio: Develops organ-on-chip and microphysiological systems for drug discovery, directly comparable to Polyphron's use of 3D tissue constructs as biological test units for pharma partners.
  • Cellino: Automates iPSC manufacturing via optical bioprocessing and has collaborated with Polyphron on cross-donor tissue manufacturing; directly comparable in the iPSC and tissue platform space.
  • Axol Bioscience: Produces iPSC-derived neurons, cardiomyocytes and other cell types for disease modeling and drug discovery; comparable as an iPSC-derived tissue/cell supplier serving pharma and academic customers.
  • TARA Biosystems (Bio-Techne): Develops human iPSC-derived cardiac and other tissues for drug discovery and safety testing; operates in the same cardiac tissue foundry category as Polyphron's cardiac program.

Broad incumbents

  • Recursion Pharmaceuticals: Operates a large-scale AI-driven biology platform combining wet-lab automation with computational models to generate training data; concept-level comparator to Polyphron's tissue foundry + biological simulator thesis.

Emerging players

  • Cytovia Therapeutics: Develops iPSC-derived cell therapies including NK and T-cell platforms; adjacent peer in the iPSC-derived therapeutic space where Polyphron's tissue transplantation program operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Polyphron social profiles

Digital presence

Polyphron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polyphron leadership team

Management profile

Number of profiles

Polyphron funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polyphron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyphron

What does Polyphron do?

Polyphron operates an autonomous tissue foundry platform that uses AI, Bayesian optimization, and automated wet-lab systems to manufacture human tissue from induced pluripotent stem cells (iPSCs) at scale. It produces high-throughput 3D tissue constructs, continuously monitors them via non-destructive AI phenotyping, and sells these tissue units as immune-compatible therapeutic grafts and as validation substrate for AI-driven drug discovery, alongside a biological simulator trained on the causal interventional data the foundry generates.

Is Polyphron a public or private company?

Polyphron is a private company. It is classified as venture growth investor backed and is currently operating.

When was Polyphron founded?

Polyphron was founded in 2024. It employs 1 to 10 people.

Where is Polyphron based?

Polyphron is headquartered in New City, United States, in the North America region.

How does Polyphron make money?

Two revenue lines are on record. Therapeutic Tissue Grafts are the primary driver. The others are AI Validation Substrate Services.

Who are Polyphron's main competitors?

Direct peers on record are Emulate, BIT Bio, Organoid Therapeutics, Curi Bio, CN Bio, Cellino, Axol Bioscience and TARA Biosystems (Bio-Techne). Recursion Pharmaceuticals is listed as a broad incumbent. Cytovia Therapeutics is listed as an emerging player.

Does Polyphron have an API?

No public API is recorded for Polyphron.

What industry is Polyphron in?

Polyphron's product category is AI-driven Tissue Manufacturing Platform. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AlleyWatchPolyphron Raises $20M to Predict Drug Toxicity in Human Tissue Before Clinical TrialsPolyphron raised $20M in seed funding led by Quiet Capital to train AI models on living human tissue for drug toxicity prediction. The company manufactures cardiac tissue and plans to expand to liver and over 20 donors. It aims to become a simulation environment for human biology before clinical trials.FinSMEsPolyphron Raises $20M in Seed FundingPolyphron, a NYC-based artificial human biology company, raised $20M in seed financing led by Quiet Capital with participation from Gradient, Haystack, and Compound. The funds will build its physical and simulated verification substrate for testing therapeutic hypotheses, expanding tissue production from cardiac to liver tissues.Venture Capital Access OnlinePolyphron Raises $20M to Build Physical Verification Layer for AI-Driven BiologyPolyphron raised $20M in seed financing led by Quiet Capital to build a physical verification layer for AI-driven biology. The company manufactures and simulates human tissue, with cardiac tissue now in production and liver planned for this year. The goal is to predict drug toxicity and patient response before clinical trials.BioSpacePolyphron and Cellino Show Tissue Manufacturing Works Across Any Patient BackgroundPolyphron and Cellino published results demonstrating that Polyphron's autonomous tissue foundry platform can manufacture structured human tissue across genetically diverse, patient-derived iPSC lines without re-optimizing for each new donor. The study showed that despite over 2,000 differentially expressed genes between donor lines at baseline, the platform converged on high-quality 3D neural tissue in all four cases using computational cross-donor optimization from sparse data. The companies plan to expand their collaboration, with Polyphron CEO stating the results change the unit economics of autologous tissue manufacturing by reframing donor variability as a programmable variable.